Influenza vaccine

Coronavirus (COVID-19) Update: FDA Holds Advisory Committee Meeting to Discuss Authorization of COVID-19 Vaccine Candidate as Part of Agency's Review of Safety and Effectiveness Data

Retrieved on: 
Thursday, December 10, 2020
Health sciences, Health, Medicine, COVID-19 vaccine, Medical research, Vaccines, Food and Drug Administration, Clinical trial, Vaccine, Influenza research, Influenza vaccine

The FDA recognizes that transparency and dialogue are critical to building public confidence in COVID-19 vaccines.

Key Points: 
  • The FDA recognizes that transparency and dialogue are critical to building public confidence in COVID-19 vaccines.
  • These data include, but are not limited to clinical trial data, non-clinical data on the development of the vaccine in the lab, and manufacturing data on how the vaccine is made.
  • FDA career officials have been reviewing the data and information ahead of the public advisory committee meeting to ensure a robust discussion with the independent experts.
  • In this time of great urgency, FDA staff feel the responsibility to move as quickly as possible through the review process.

Global Vaccines Market Report 2020-2027: Key Market Opportunities in the Robust Pipeline of Vaccines

Retrieved on: 
Thursday, December 10, 2020
Vaccination, Medical specialties, Virology, Medicine, Clinical medicine, Vaccine, Vaccines, Attenuated vaccine, Vaccine hesitancy, Influenza vaccine

The global vaccines market is expected to reach US$ 64,538.4 Mn in 2027 from US$ 39,128.3 Mn in 2019.

Key Points: 
  • The global vaccines market is expected to reach US$ 64,538.4 Mn in 2027 from US$ 39,128.3 Mn in 2019.
  • The report highlights the trends prevalent in the global vaccines market and the factors driving the market along with those that act as deterrents to its growth.
  • The vaccines market by technology is segmented into Recombinant vaccines, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, and Toxoid Vaccines.
  • On the other hand, robust pipeline of vaccines is likely to have a positive impact on the growth of the global vaccines market in the coming years.

Report: Nearly Half Of Health Center Patients Qualify For Phase One COVID Vaccinations

Retrieved on: 
Wednesday, December 9, 2020
Health sciences, Medicine, Health, COVID-19 vaccine, Medical research, Vaccine, Vaccines, Vaccination, Centers for Disease Control and Prevention, Preventive healthcare, Influenza vaccine, HPV vaccine

BETHESDA, Md., Dec. 9, 2020 /PRNewswire/ -- Nearly half of all patients that Community Health Centers serve qualify for Phase One COVID-19 immunizations under priority guidelines established by the Centers for Disease Control and Prevention (CDC) according to a new report.

Key Points: 
  • BETHESDA, Md., Dec. 9, 2020 /PRNewswire/ -- Nearly half of all patients that Community Health Centers serve qualify for Phase One COVID-19 immunizations under priority guidelines established by the Centers for Disease Control and Prevention (CDC) according to a new report.
  • Health centers are positioned to play a major role in ensuring the COVID-19 vaccine reaches high-risk populations.
  • Health centers serve urban, rural, and frontier communities that otherwise face significant barriers to care, which is particularly problematic for vaccines requiring two different clinical visits.
  • Protecting health center workers on the front lines is also a vital concern as 22,751 health center staff have already been infected by the virus.Assuming health centers provide two dose vaccines to all health center staff, their 30 million patients, and many additional community residents, preliminary estimates of vaccinations and related costs are at least $2.73 billion.

USA Equities Corp. (USAQ) and AllergiEnd Announces Allergy Testing Kit Distribution ahead of COVID-19 Vaccine

Retrieved on: 
Thursday, December 10, 2020
Medical specialties, Medicine, Health care, Vaccination, Virology, Vaccines, Vaccine, Adverse effect, Allergy, Vaccine hesitancy, Influenza vaccine

This news comes after two healthcare professionals, both with a history of anaphylactoid reactions, suffered adverse side effects to the vaccine.

Key Points: 
  • This news comes after two healthcare professionals, both with a history of anaphylactoid reactions, suffered adverse side effects to the vaccine.
  • As the United States waits for the vaccine, this news from the U.K. is a cautionary warning.
  • Physicians should begin making preparations ahead of time for those patients with a history of allergic reactions.
  • Despite the uncertainty surrounding this vaccine, physicians can alleviate the patient's worry by providing an allergy test ahead of vaccination.

2020 Seasonal Influenza Vaccines Market Report: Completion of Conversion to QIVs will Drive Incremental Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 10, 2020
Retail, Other Retail, Medical specialties, Drugs, Vaccines, Influenza vaccines, Influenza vaccine, Vaccination, Sanofi, Virology, Protein Sciences, CSL Limited, Flu season, Live attenuated influenza vaccine

Three major manufacturers dominate the seasonal influenza vaccines market, namely GlaxoSmithKline, Seqirus, and Sanofi, with 2019 vaccines sales of $684m, $799m, and $2,144m, respectively.

Key Points: 
  • Three major manufacturers dominate the seasonal influenza vaccines market, namely GlaxoSmithKline, Seqirus, and Sanofi, with 2019 vaccines sales of $684m, $799m, and $2,144m, respectively.
  • Both Flucelvax QIV and Flublok QIV are expected to experience sales growth following anticipated regulatory approvals in the EU in Q4 2020.
  • The 2020 EU approvals of CSL's Fluad QIV and Sanofi's Fluzone HD QIV mark significant opportunities for both manufacturers.
  • Additionally, universal vaccines should be able to provide protection against new pandemic strains that may arise, which the seasonal influenza vaccine is unable to do.

2020 Infectious Diseases Disease Analysis - Seasonal Influenza Vaccines - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 9, 2020
Health, Infectious diseases, Vaccination, Drugs, Medical specialties, Vaccines, Influenza vaccines, Influenza vaccine, Vaccine, Influenza, Flu season, Live attenuated influenza vaccine, Seasonal influenza vaccine brands, Quadrivalent vaccine

The "Infectious Diseases Disease Analysis: Seasonal Influenza Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Infectious Diseases Disease Analysis: Seasonal Influenza Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • The seasonal influenza vaccines market in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) is expected to continue to expand over the next 10 years, largely due to the continued uptake of premium-priced vaccines in the elderly subgroup, including quadrivalent forms of Fluzone High-Dose (HD) and Fluad, as well as the launch of the first-in-class adjuvanted nanoparticle vaccine, NanoFlu.
  • Further to this, an aging population in the US, Japan, five major European markets, and other developed countries will increase the number of patients, where coverage rates are higher.
  • Additionally, the COVID-19 pandemic has prompted an unexpected surge in demand for influenza vaccines due to heightened public awareness of the threat posed by respiratory viruses to the elderly and those with co-morbidities, as well as the potential burden on healthcare services of coinciding COVID-19 and influenza waves.

Bank of America Joins CVS Health to Fund and Deliver Free Flu Vaccine Vouchers

Retrieved on: 
Wednesday, December 9, 2020
Finance, Banking, Professional services, Hispanic, Philanthropy, Other Health, Health, Consumer, Other Philanthropy, Articles, Woonsocket, Rhode Island, Organizations, Health, CVS Health, Influenza vaccine, Influenza A virus subtype H1N1, World Health Organization

Underserved communities have been hit particularly hard by COVID-19, so supporting flu prevention in these communities is even more important, said Eileen Howard Boone, senior vice president of Corporate Social Responsibility and Philanthropy, CVS Health.

Key Points: 
  • Underserved communities have been hit particularly hard by COVID-19, so supporting flu prevention in these communities is even more important, said Eileen Howard Boone, senior vice president of Corporate Social Responsibility and Philanthropy, CVS Health.
  • Working together with other community-minded companies like Bank of America and our nonprofit partners, we are able to expand our reach to individuals who may not otherwise have access to flu vaccines.
  • Bank of Americas work with CVS Health and the companys ongoing PPE donations build on its continued health and health care-focused investments in the communities it serves.
  • Recent Bank of America announcements focused on racial equality, diversity and inclusion, and economic opportunity include:

Health Officials Stress Importance of Flu Vaccinations Amid the Rise in COVID-19 Cases During National Influenza Vaccination Week (December 6-13)

Retrieved on: 
Wednesday, December 9, 2020
Influenza, Medical specialties, Health, Medicine, Flu season, Seasonality, Influenza vaccine, Swine flu pandemic, Swine influenza

With the recent spike in COVID-19 cases, a severe flu season could mean dangerous, simultaneous respiratory infections that could overrun already stressed clinics and hospitals.

Key Points: 
  • With the recent spike in COVID-19 cases, a severe flu season could mean dangerous, simultaneous respiratory infections that could overrun already stressed clinics and hospitals.
  • "And this year, getting the flu shot is ever more critical as health officials work to avoid a dangerous and even deadly 'twindemic' of people getting the flu in addition to COVID-19."
  • Getting a flu vaccine has been shown to reduce the risk of getting sick, being hospitalized or dying from flu.
  • In 2019-2020, flu vaccination prevented an estimated 7.52 million illnesses, 3.69 million medical visits, 105,000 hospitalizations and 6,300 deaths due to influenza.

Seqirus Presents Real-World Data for Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) at ESWI 2020

Retrieved on: 
Wednesday, December 9, 2020
Vaccination, Drugs, Medical specialties, Vaccines, Influenza vaccines, Influenza vaccine, Influenza, Vaccine, Live attenuated influenza vaccine, Flu season, Quadrivalent vaccine, Seasonal influenza vaccine brands

"Influenza is an incredibly variable virus, so having real-world data in addition to randomized control trial data allows us to have a better understanding of the effectiveness of seasonal influenza vaccines under varying circumstances."

Key Points: 
  • "Influenza is an incredibly variable virus, so having real-world data in addition to randomized control trial data allows us to have a better understanding of the effectiveness of seasonal influenza vaccines under varying circumstances."
  • As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.
  • You should not get FLUCELVAX QUADRIVALENT if you have had a severe allergic reaction to any of the ingredients in the vaccine.
  • The decision to give FLUCELVAX QUADRIVALENT should be made by your healthcare provider, based on careful consideration of the potential benefits and risks.

Mediaplanet and Flu Survivor Latasha Haynes Team Up for Fighting the Flu

Retrieved on: 
Tuesday, December 8, 2020
Medical specialties, Influenza A virus subtype H1N1, Influenza vaccine, Health care, Medicine, Influenza, Animal virology

NEW YORK, Dec. 8, 2020 /PRNewswire-PRWeb/ -- Helping to conclude National Influenza Vaccination Week, Mediaplanet today announces the launch of this December's edition of "Fighting the Flu."

Key Points: 
  • NEW YORK, Dec. 8, 2020 /PRNewswire-PRWeb/ -- Helping to conclude National Influenza Vaccination Week, Mediaplanet today announces the launch of this December's edition of "Fighting the Flu."
  • While most people fully recover from bouts of flu, in some cases the illness can become extremely dangerous or even fatal.
  • Haynes' near-death experience with the flu inspired her to become an advocate with Families Fighting Flu (FFF), a national, nonprofit advocacy organization that's dedicated to protecting children, families, and communities against the flu.
  • As part of this campaign, Haynes is sharing her story and what you can do to prevent flu.